Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report
Plain-language summary
This case report describes a woman with metastatic ALK-rearranged non-small cell lung cancer who was treated with the ALK inhibitor alectinib throughout two pregnancies, both of which had uncomplicated obstetrical and postnatal courses. Because safety data for alectinib during pregnancy are limited, the authors note this as only the second such reported case, and in it the drug did not appear to affect fetal or early childhood development. They caution that this does not exclude undetectable or delayed toxic effects and that additional study is needed.
Read the full paper (DOI: 10.1016/j.jtocrr.2022.100361).
This is a plain-language summary written for discoverability; the authoritative version is the published paper. Part of Travis Osterman's peer-reviewed publications.